Sanofi SA (SASY)

103.66 -0.06 (-0.06%)
Real-time Data EUR Disclaimer

SASY Financial Summary

For the three months ended 31 March 2022, Sanofi SA revenues increased 13% to EUR10.05B. Net income increased 28% to EUR2.01B. Revenues reflect Pharmaceuticals segment increase of 41% to EUR7.4B, Vaccines segment increase of 18% to EUR1.24B, Consumer Healthcare-Allergy, Cold & Cough segment increase of 39% to EUR347M, United States segment increase of 20% to EUR3.48B, China segment increase of 24% to EUR901M, Europe segment increase of 7% to EUR2.39B.
TTM
Trailing Twelve Months
MRQ
Most Recent Quarter
SASY
Gross margin TTM 69.14%
Operating margin TTM 20.98%
Net Profit margin TTM 16.5%
Return on Investment TTM -
Total Revenue
Net Income
Title
Mar 31, 2022
Dec 31, 2021
Sep 30, 2021
Jun 30, 2021
Total Revenue 10,053 21,244 10,829 17,931
Gross Profit 7,173 14,530 7,591 12,390
Operating Income 2,397 4,513 3,042 3,613
Net Income 2,009 3,447 2,317 2,776
Clear All
0Selected
Please try another search
SASY
Quick Ratio MRQ -
Current Ratio MRQ -
LT Debt to Equity MRQ -
Total Debt to Equity MRQ -
Total Assets
Total Liabilities
Title
Mar 31, 2022
Dec 31, 2021
Sep 30, 2021
Jun 30, 2021
Total Assets 120,242 112,321
Total Liabilities 51,561 49,084
Total Equity 68,681 63,237
Clear All
0Selected
Please try another search
SASY
Cash Flow/Share TTM 6.61
Revenue/Share TTM 32.15
Operating Cash Flow -
Cash
Net Change in Cash
Title
Mar 31, 2022
Dec 31, 2021
Sep 30, 2021
Jun 30, 2021
Cash From Operating Activities 10,522 4,754
Cash From Investing Activities -7,298 -2,339
Cash From Financing Activities -7,056 -6,616
Net Change in Cash -3,817 -4,193
Clear All
0Selected
Please try another search

* In Millions of EUR (except for per share items)

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.